Key facts
- It has raised $13.2M across 1 recorded rounds; the latest was Early Stage VC ($13.2M) in Mar 2023.
- Corista has filed 1 Form D with the SEC, most recently Dec 2025 ($13.2M sold to 77 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·Watchlist + deal alerts for Corista
Funding rounds
1 roundsAbout Corista
Developer of a workflow management platform designed for pathology labs to better manage the work. The company's platform offers users to view and manage their own cases in an image-centric pathology workflow with the tools needed to review, annotate, collaborate, and generate customized synoptic reports for referring pathologists, tumor boards, and other requirements, with digital image access for viewing by a remote client, enabling pathologists and other physicians to manage the pathology labs efficiently.
- Sector
- Healthcare
- HQ
- Concord, MA, United States
- Founded
- 2005
- Employees
- 36
- Website
- corista.com/
- Ownership
- Privately Held (backing)
Corista doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Corista shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Corista in its N-PORT filings yet. We sweep new filings monthly.